daunorubicin,cytarabine
Not Tagged
['leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'vyxeos']
#asco23 #leusm lin: relapse after allohct remains a problem for older aml pts undergoing ric allo, but many improvements in gvhd ppx &amp; supportive care (eg, letermovir) particularly helpful in this pop. bridge to allo options also better hma/ven or vyxeos. iomab-b soon, too. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)